Side-by-side comparison of AI visibility scores, market position, and capabilities
Major ambulatory EHR serving 150K providers bootstrapped to scale; Sunoh.ai ambient clinical documentation and revenue cycle management competing with Epic and athenahealth for practices.
eClinicalWorks is one of the largest electronic health record (EHR) and practice management software providers in the United States, serving approximately 150,000 providers across 850,000 care sites with ambulatory EHR, revenue cycle management, patient engagement, and population health tools. Founded in 1999 by Girish Navani and headquartered in Westborough, Massachusetts, eClinicalWorks is privately held and is notable for being a bootstrapped company that has grown to significant scale without venture capital funding, generating substantial annual revenue from its large installed physician base.\n\neClinicalWorks' platform covers the ambulatory (outpatient) clinical workflow: clinical documentation with specialty-specific templates, order entry for labs and imaging, e-prescribing, chronic disease management registries, telehealth (healow TeleVisits), and patient portal. The revenue cycle management capabilities handle insurance claims submission, denial management, and patient billing. Population health tools enable practices and health systems to identify at-risk patient populations and coordinate care across attributed patients.\n\nIn 2025, eClinicalWorks competes with Epic (the dominant health system EHR), athenahealth (cloud-native ambulatory EHR), Oracle Health (Cerner), and Modernizing Medicine for physician practice EHR market share. The company has faced regulatory challenges — in 2017, eClinicalWorks paid $155 million to settle Department of Justice charges related to EHR certification fraud. Despite this, the company retained most of its customer base due to high switching costs inherent in EHR changes. The 2025 strategy focuses on its AI assistant Sunoh.ai (ambient clinical documentation that automatically generates SOAP notes from recorded patient visits), expanding telehealth capabilities, and growing the healow patient engagement platform.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.